Exclusive special offer and discount title banner vector image

JTA-004 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032

SCOPE OF THE REPORT

JTA-004 Osteoarthritis Drug Pipeline: 7 Major Market’s Analysis (Market Size of Jta-004 in The 7 Major Markets for Osteoarthritis) Country Analysis (Japan, Germany, United States, France, Italy, Spain, United Kingdom)

REQUEST CUSTOMIZATION

MARKET OVERVIEW

JTA-004 is an innovative treatment in development for managing knee osteoarthritis pain through intra-articular injections. This advanced osteoarthritis (OA) medicine features a proprietary blend of hyaluronic acid and plasma protein, substances naturally present in the synovial fluid of joints, along with a fast-acting analgesic. JTA-004 aims to improve joint lubrication, protect cartilage in osteoarthritic joints, and deliver effective pain relief, addressing both the mechanical and symptomatic aspects of osteoarthritis, which is becoming increasingly common among osteoarthritis patients.

This drug is developed by BioSenic SA, a biotechnology company specializing in products for immunity, autoimmune diseases, and organ repair. BioSenic was established through a reverse merger between Bone Therapeutics and Medsenic. The company emphasizes cell therapy and the therapeutic use of arsenic trioxide (As₂O₃). Founded in 2006, BioSenic is headquartered in Belgium.

JTA004-pipeline

To Know More About This Report, Request a Free Sample Copy

MARKET POTENTIAL & POSITIONING

JTA-004, developed by BioSenic, addresses a significant gap in the treatment of osteoarthritis knee pain. This investigational intra-articular injection combines hyaluronic acid, plasma proteins, and clonidine to enhance joint lubrication, protect cartilage, and provide immediate pain relief. Osteoarthritis signs and symptoms, such as severe pain and inflammation, are the primary focus of this treatment, particularly for those suffering from advanced osteoarthritis.

Although the initial Phase III clinical trial did not meet its primary and secondary endpoints, JTA-004 demonstrated a favorable safety profile. A subsequent post-hoc analysis by BioSenic, in collaboration with Artialis, revealed that a specific subset of patients—those with the most severe and inflammatory forms of knee osteoarthritis—experienced significant pain relief compared to both placebo and active comparators.

This new insight suggests that JTA-004 may be especially effective for a specific group of patients, enabling a more targeted approach in future trials. BioSenic’s continued efforts to re-evaluate and refine the therapeutic profile of JTA-004 highlight its potential to establish a unique position in the competitive osteoarthritis treatment market.

INKWOOD RESEARCH OFFERS AN ANALYSIS OF SEVEN KEY MARKETS

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
    • Osteoarthritis (OA) is becoming an increasingly significant public health issue in Japan, driven by the country’s rapidly aging population. As of September 15, 2023, Japan’s senior population, defined as individuals aged 65 and older, has reached 36.2 million, according to data from the Ministry of Internal Affairs and Communications. This demographic shift presents substantial challenges for Japan’s healthcare system and economy.
    • In Japan, knee osteoarthritis is notably prevalent among adults over the age of 60. This high prevalence can be partly attributed to cultural practices and lifestyle habits, which frequently involve knee-intensive activities like kneeling and squatting.
    • The burden of osteoarthritis (OA) in Japan is significant, resulting in higher healthcare costs and a growing need for joint replacement surgeries. As the population continues to age, the prevalence of OA is anticipated to increase, highlighting the need for public health interventions and the development of new treatments.

TABLE OF CONTENTS

  1. INTRODUCTION TO THE REPORT
  2. JTA-004 OVERVIEW
    1. PRODUCT DETAIL
    2. CLINICAL DEVELOPMENT
      1. CLINICAL STUDIES
      2. CLINICAL TRIALS INFORMATION
      3. SAFETY AND EFFICACY
    3. OTHER DEVELOPMENTAL ACTIVITIES
    4. PRODUCT PROFILE
  3. COMPETITIVE LANDSCAPE 
    1. MARKETED THERAPIES
    2. LATE-STAGE EMERGING THERAPIES
  4. JTA-004 MARKET ASSESSMENT
    1. MARKET OUTLOOK OF JTA-004 IN OSTEOARTHRITIS
  5. 7 MAJOR MARKET’S ANALYSIS
    1. MARKET SIZE OF JTA-004 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
    2. 7 COUNTRY ANALYSIS
      1. MARKET SIZE OF JTA-004 IN UNITED STATES FOR OSTEOARTHRITIS
      2. MARKET SIZE OF JTA-004 IN GERMANY FOR OSTEOARTHRITIS
      3. MARKET SIZE OF JTA-004 IN FRANCE FOR OSTEOARTHRITIS
      4. MARKET SIZE OF JTA-004 IN ITALY FOR OSTEOARTHRITIS
      5. MARKET SIZE OF JTA-004 IN SPAIN FOR OSTEOARTHRITIS
      6. MARKET SIZE OF JTA-004 IN UNITED KINGDOM FOR OSTEOARTHRITIS
      7. MARKET SIZE OF JTA-004 IN JAPAN FOR OSTEOARTHRITIS
  6. SWOT ANALYSIS
  7. ANALYST PERSPECTIVE

LIST OF TABLES

TABLE 1: JTA-004, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 2: JTA-004, GENERAL DESCRIPTION

TABLE 3: MARKETED THERAPIES

TABLE 4: EMERGING THERAPIES

TABLE 5: JTA-004 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

TABLE 6: JTA-004 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

TABLE 7: JTA-004 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

TABLE 8: JTA-004 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

TABLE 9: JTA-004 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

TABLE 10: JTA-004 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

TABLE 11: JTA-004 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

TABLE 12: JTA-004 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

LIST OF FIGURES

FIGURE 1: JTA-004 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

FIGURE 2: JTA-004 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

FIGURE 3: JTA-004 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

FIGURE 4: JTA-004 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

FIGURE 5: JTA-004 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

FIGURE 6: JTA-004 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

FIGURE 7: JTA-004 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

FIGURE 8: JTA-004 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

FAQs

A: JTA-004 works by leveraging three key components: hyaluronic acid for joint lubrication and cartilage protection, plasma proteins that support joint health, and clonidine, a fast-acting analgesic that helps relieve pain. The combination is designed to address both the mechanical and symptomatic aspects of knee osteoarthritis.

A: JTA-004 is administered as a single injection directly into the knee joint. This localized delivery allows the therapy to act directly on the affected area, providing targeted relief from osteoarthritis symptoms.

A: JTA-004 stands out due to its combination of multiple therapeutic actions—lubrication, cartilage protection, and pain relief—in a single injection. Moreover, the discovery of a specific patient subset that responds particularly well to the treatment underscores its potential for personalized therapy, distinguishing it from other treatments that may lack this level of specificity.

Request Customization
Request Customization
Request free sample